185 related articles for article (PubMed ID: 32576496)
1. Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study.
Turpin A; de Baere T; Heurgué A; Le Malicot K; Ollivier-Hourmand I; Lecomte T; Perrier H; Vergniol J; Sefrioui D; Rinaldi Y; Edeline J; Jouve JL; Silvain C; Becouarn Y; Dauvois B; Baconnier M; Debette-Gratien M; Deplanque G; Dharancy S; Lepage C; Hebbar M;
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101464. PubMed ID: 32576496
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib versus sorafenib plus transarterial chemoembolization for inoperable hepatocellular carcinoma patients.
Xu Q; Huang Y; Shi H; Song Q; Xu Y
J BUON; 2018; 23(1):193-199. PubMed ID: 29552783
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Chen J; Zhou C; Long Y; Yin X
Tumour Biol; 2015 Jan; 36(1):183-91. PubMed ID: 25217986
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, Safety, and Potential Biomarkers of Sunitinib and Transarterial Chemoembolization (TACE) Combination in Advanced Hepatocellular Carcinoma (HCC): Phase II Trial.
Pokuri VK; Tomaszewski GM; Ait-Oudhia S; Groman A; Khushalani NI; Lugade AA; Thanavala Y; Ashton EA; Grande C; Fetterly GJ; Iyer R
Am J Clin Oncol; 2018 Apr; 41(4):332-338. PubMed ID: 27014931
[TBL] [Abstract][Full Text] [Related]
5. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
[TBL] [Abstract][Full Text] [Related]
6. Benefits of step-by-step debulking microwave ablation for huge unresectable hepatocellular carcinoma patients after transcatheter arterial chemoembolization refractoriness.
Huang T; Qi H; Shen L; Wu Y; Song Z; Cao F; Liu Y; Xie L; Chen S; Tang T; Li H; Zhang Y; Feng L; Zhang H; Chen J; Fan W
Int J Hyperthermia; 2022; 39(1):935-945. PubMed ID: 35853727
[TBL] [Abstract][Full Text] [Related]
7. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
[TBL] [Abstract][Full Text] [Related]
8. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study.
Lu H; Ye Q; Zheng C; Fan L; Xia X
BMC Cancer; 2023 Mar; 23(1):270. PubMed ID: 36964538
[TBL] [Abstract][Full Text] [Related]
10. Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma.
Zhang S; Zhao Y; He L; Bo C; An Y; Li N; Ma W; Guo Y; Guo Y; Zhang C
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101851. PubMed ID: 34923180
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection.
Song Q; Ren W; Fan L; Zhao M; Mao L; Jiang S; Zhao C; Cui Y
Dig Dis Sci; 2020 Apr; 65(4):1266-1275. PubMed ID: 31312995
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
[TBL] [Abstract][Full Text] [Related]
14. Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma.
English K; Brodin NP; Shankar V; Zhu S; Ohri N; Golowa YS; Cynamon J; Bellemare S; Kaubisch A; Kinkhabwala M; Kalnicki S; Garg MK; Guha C; Kabarriti R
JAMA Netw Open; 2020 Nov; 3(11):e2023942. PubMed ID: 33151315
[TBL] [Abstract][Full Text] [Related]
15. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
[TBL] [Abstract][Full Text] [Related]
16. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.
Megías Vericat JE; García Marcos R; López Briz E; Gómez Muñoz F; Ramos Ruiz J; Martínez Rodrigo JJ; Poveda Andrés JL
Radiologia; 2015; 57(6):496-504. PubMed ID: 25857250
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma.
Li M; Lu C; Cheng J; Zhang J; Cao C; Xu J; Xu J; Pan H; Zhong B; Tucker S; Wang D
J Gastroenterol Hepatol; 2009 Aug; 24(8):1437-44. PubMed ID: 19486255
[TBL] [Abstract][Full Text] [Related]
18. Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
Nabavizadeh N; Jahangiri Y; Rahmani R; Tomozawa Y; Geeratikun Y; Chen Y; Hung A; Degnin C; Farsad K
AJR Am J Roentgenol; 2021 Sep; 217(3):691-698. PubMed ID: 32997517
[No Abstract] [Full Text] [Related]
19. Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC).
Lin XJ; Li QJ; Lao XM; Yang H; Li SP
BMC Cancer; 2015 Oct; 15():707. PubMed ID: 26470869
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]